Application
Figure 1: FCM analysis CD3 expressed in human peripheral blood cells.IF
(A–C) Different isoforms of T lymphocytes infiltration in tumor tissues detected by immunofluorescence assay. (D) M1 macrophage infiltration in tumor tissues detected by immunofluorescence assay.IF
The effect of the combination treatment on T-lymphocyte infiltration in the tumor tissue. The expression of CD4+ (A) and the CD8+ (B) T cells in the tumor tissue after treatment with different therapies for 14 days. C. The expression of Granzyme in the tumor tissue in each group after treatment for 14 days.IF
(C) Infiltration of CD4+ T lymphocytes. (D) Infiltration of CD8+ T lymphocytes in tumor tissues.IF
A-D. Immunofluorescence was used to detect the infiltration of immune cells in tumour tissue.| Product Name | CD3 |
|---|---|
| Antibody Type | Primary Antibodies |
| Immunogen | Purified recombinant fragment of human CD3 expressed in E. Coli. |
| Clonality | Monoclonal |
|---|---|
| Host Species | Unknow |
| Tested Applications | IF |
| ICC/IF:1:100~1:200 Notes:Optimal dilutions/concentrations should be determined by the researcher. |
| Alternative Names | T3Z CD247 |
|---|---|
| Molecular Weight(MW) | N/A |
| Entrez Gene | 919 |
|---|
Application
Figure 1: FCM analysis CD3 expressed in human peripheral blood cells.
IF
(A–C) Different isoforms of T lymphocytes infiltration in tumor tissues detected by immunofluorescence assay. (D) M1 macrophage infiltration in tumor tissues detected by immunofluorescence assay.
IF
The effect of the combination treatment on T-lymphocyte infiltration in the tumor tissue. The expression of CD4+ (A) and the CD8+ (B) T cells in the tumor tissue after treatment with different therapies for 14 days. C. The expression of Granzyme in the tumor tissue in each group after treatment for 14 days.
IF
(C) Infiltration of CD4+ T lymphocytes. (D) Infiltration of CD8+ T lymphocytes in tumor tissues.
IF
A-D. Immunofluorescence was used to detect the infiltration of immune cells in tumour tissue.| Application Notes | ICC/IF:1:100~1:200 Notes:Optimal dilutions/concentrations should be determined by the researcher. |
|---|
| Form | Ascitic fluid containing 0.03% sodium azide. |
|---|---|
| Storage Instructions | 4℃; -20℃ for long term storage |
